TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Cyble’s 2026 healthcare threat report flags a sharp rise in Asia-focused ransomware, with hospitals, elderly care, and diagnostic systems increasingly in cybercriminal crosshairs
The new capital is expected to fund the company through 2029
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
The center combines rigorous scientific instruction with practical, hands-on training, equipping providers with the clinical, consultative, and business skills needed to deliver safe, effective, and patient-centered care
Subscribe To Our Newsletter & Stay Updated